Uppsala, Sweden July 25: Cavidi AB, developer of the Exazym® BOLD (Binding Oligo Ladder Detection) signal amplification platform, today announced the commercial launch of Exazym® StreptaClick® Primer, a new reagent that enables researchers to add BOLD amplification directly to any sandwich ELISA using a biotinylated detector antibody — without conjugation chemistry or changes to the existing assay workflow.
Simplifying the path to BOLD amplification on commercial ELISAs
The Exazym platform amplifies immunoassay signals by coupling an oligo-dT primer to the detector antibody, driving a polymerase reaction that multiplies signal output dramatically while leaving the assay’s capture antibody, plate format, and reader unchanged. Until now, implementing BOLD required custom conjugation of the detector antibody using the Exazym® ClickChem Conjugation Kit.
StreptaClick® Primer removes that requirement for the large subset of assays that already use biotinylated detector antibodies. The product is a pre-formed streptavidin-oligo-dT conjugate, quality-controlled and ready to use. Researchers add it at the detection step of their existing ELISA protocol. No offline chemistry, no additional incubation equipment, and no changes to coating, blocking, or sample addition steps are required.
Demonstrated performance across commercial assay formats
In real-world studies, StreptaClick® Primer delivered an 11-fold improvement in limit of detection on the R&D Systems Human IL-23 DuoSet and a 16-fold improvement on the Mabtech Human IL-4 ELISA Flex. Typical sensitivity gains across assays range from 10 to 100-fold. The degree of improvement scales with the signal-to-noise characteristics of the underlying assay — assays with low intrinsic background tend to see the largest gains.
Optimization requires cross-titrating two parameters: the concentration of the biotinylated detector antibody and the StreptaClick® Primer concentration. Full optimization guidance is provided in the product Instructions for Use and in published application notes available on the Cavidi website.
Jonathan Royce, CEO at Cavidi AB, said: “Most labs running cytokine or biomarker ELISAs today are already using biotinylated detection antibodies — that’s a very large installed base of assays that can now access BOLD amplification with essentially no workflow redesign. StreptaClick® Primer is the answer to the question we hear most often: what’s the fastest way to get started with Exazym?”
Availability
Exazym® StreptaClick® Primer is available now directly from Cavidi and through authorised distributors. First-time Exazym users require three components: StreptaClick® Primer, the Exazym® Polymerase Reaction Kit, and an Exazym® Detection Kit appropriate for their detection modality (HRP, biotin, APC, or PE). Full product information, performance data, application notes, and ordering are available at cavidi.se/product/exazym-streptaclick-primer/.